prognostic markers in mcl and the value of car-t therapy in treating high-risk disease
Published 2 years ago • 145 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
1:06
assessing metabolic tumor volume as a prognostic marker before car-t therapy for dlbcl
-
0:59
identifying molecular markers for the prediction of icaht in patients receiving car t-cell therapy
-
2:03
prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy
-
5:35
clinical and prognostic significance of aberrant t-cell marker expression in aml
-
3:50
relevance of current prognostication and prediction markers for cll with new targeted therapies
-
3:16
prognostic markers for the treatment of cll
-
2:35
inflammatory biomarkers as predictors of car-t efficacy in multiple myeloma
-
3:14
using machine learning to identify trajectories of hematotoxicity following car t-cell therapy
-
3:30
risk assessment and prognosis in mcl
-
1:59
the role of mrd as a prognostic & predictive biomarker in cll
-
0:58
the potential of car-t therapy targeting mutant calr in myelofibrosis & essential thrombocythemia
-
1:14
prognostic markers for cll - how do they help determine who gets which treatment?
-
1:19
the prognostic value of mrd in cll
-
3:38
finding the expansion balance: car t-cell response markers identified from the trial of jcar017
-
2:04
autologous transplantation followed by maintenance vs maintenance alone in patients with mcl
-
3:45
mrd: a prognostic marker in targeted therapy
-
6:28
prognostic markers and mrd in cll
-
5:36
mcl0208: identification of novel genomic prognostic factors
-
1:05
the prognostic and potentially therapeutic value of liquid biopsy in multiple myeloma